Biomarkers Associated with Safety & Efficacy of Dual Targeting CAR-T Therapies to Treat Lymphoma
- Highlighting biomarker data associated with clinical safety, efficacy from Prizlo-cel anti-CD19/CD20 CAR-T therapy
- Showcasing early efficacy results to illustrate how dual targeting improves clinical response
- Utilizing early success to inform next steps towards expanded clinical use